SAN DIEGO - The results of a Phase II clinical trial of ENBREL® (etanercept) in patients with psoriasis and psoriatic arthritis will be featured at the Late-Breaker Abstract Session at the American Academy of Allergy, Asthma and Immunology's (AAAAI) 56th Annual Meeting (March 3-8 in San Diego, California).
WHO: Dr. Phillip Mease, MD, a rheumatologist and lead investigator will present the results of a phase II clinical trial of ENBREL to treat patients with psoriasis and psoriatic arthritis. Dr. Mease is affiliated with the Minor and James Medical Center in Seattle, Washington.
WHEN/WHERE: 2:00 - 4:00 pm, Saturday, March 4, 2000, Late Breaker: New Therapies Mini-symposium, will take place in Room 8, Upper Level of the San Diego Convention Center and will be moderated by Dr. James Kemp and Dr. Thomas Casale.
The U.S. Food and Drug Administration (FDA) approved ENBREL on November 2, 1998 to treat moderately to severely active rheumatoid arthritis in patients who have an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). The FDA included children and teen-agers (age 4-17 years) in the ENBREL label when it granted the drug a new indication on May 28, 1999 for the treatment of moderately to severely active polyarticular-course juvenile rheumatoid arthritis patients who have had an inadequate response to one or more DMARDs.
Immunex and Wyeth-Ayerst co-market ENBREL in North America. Other Wyeth-Ayerst affiliates will market ENBREL outside of North America. Additional information about ENBREL, including full prescribing information, can be found on the company-sponsored web site at ( www.ENBREL.com).